Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.54 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26257723 | 1.00 | RECQL (0.58) | RECQLUSP2SMN1; SMN2HPGDEPHX1 | |
| SCHEMBL14401934 | 0.91 | RECQL (0.50) | RECQLUSP2SMN1; SMN2HPGDEPHX1 | |
| SCHEMBL158850 | 0.91 | RECQL (0.50) | RECQLUSP2SMN1; SMN2HPGDEPHX1 | |
| SCHEMBL2253823 | 0.91 | RECQL (0.50) | RECQLUSP2SMN1; SMN2HPGDEPHX1 | |
| SCHEMBL2251937 | 0.91 | RECQL (0.50) | RECQLUSP2SMN1; SMN2HPGDEPHX1 | |
| SCHEMBL2251944 | 0.91 | RECQL (0.50) | RECQLUSP2SMN1; SMN2HPGDEPHX1 | |
| SCHEMBL2251940 | 0.91 | RECQL (0.50) | RECQLUSP2SMN1; SMN2HPGDEPHX1 | |
| SCHEMBL26921282 | 0.84 | RECQL (0.54) | RECQLUSP2SMN1; SMN2HPGDEPHX1 | |
| SCHEMBL310117 | 0.82 | GPR119 (0.67) | RECQLUSP2SMN1; SMN2HPGDEPHX1 | |
| SCHEMBL696090 | 0.82 | HPGD (0.62) | RECQLUSP2SMN1; SMN2HPGDEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583858-B2 | TDO2 inhibitors | GENENTECH, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| EP-3394068-B1 | TDO2 INHIBITORS | GENENTECH INC (US) | 2024-09-11 | — | — | EP | disclosed |
| EP-4400172-A2 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | Incyte Holdings Corporation (US) | 2024-07-17 | — | — | EP | disclosed |
| US-20220306635-A1 | TDO2 Inhibitors | GENENTECH, INC. | 2022-09-29 | — | — | US | disclosed |
| CN-115010712-A | TDO2 inhibitors | 基因泰克公司 | 2022-09-06 | — | — | CN | disclosed |
| CN-110072864-B | TDO2 inhibitors | 基因泰克公司 | 2022-05-27 | — | — | CN | disclosed |
| US-10800780-B2 | TDO2 Inhibitors | GENENTECH, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-10800780-B2 | TDO2 Inhibitors | GENENTECH, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| EP-3715347-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | Incyte Holdings Corporation (US) | 2020-09-30 | — | — | EP | disclosed |
| US-20190016726-A1 | TDO2 Inhibitors | PHARMARON BEIJING CO. LTD. (CN) | 2019-01-17 | — | — | US | disclosed |
| US-20190016726-A1 | TDO2 Inhibitors | PHARMARON BEIJING CO. LTD. (CN) | 2019-01-17 | — | — | US | disclosed |
| EP-3354652-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | Incyte Holdings Corporation (US) | 2018-08-01 | — | — | EP | disclosed |
| WO-2017107979-A1 | TDO2 INHIBITORS | GENENTECH, INC. (US) | 2017-06-29 | — | — | WO | disclosed |
| EP-1636217-B1 | 2-IMIDAZO-BENZOTHIAZOLES AS ADENOSINE RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 2008-09-03 | — | — | EP | disclosed |
| EP-1636217-B1 | 2-IMIDAZO-BENZOTHIAZOLES AS ADENOSINE RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 2008-09-03 | — | — | EP | disclosed |
| US-7122545-B2 | Imidazo-benzothiazoles | HOFFMANN-LA ROCHE INC. (US) | 2006-10-17 | — | — | US | disclosed |
| EP-1636217-A1 | 2-IMIDAZO-BENZOTHIAZOLES AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004101558-A1 | 2-IMIDAZO-BENZOTHIAZOLES AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-25 | — | — | WO | disclosed |
| WO-2004101558-A1 | 2-IMIDAZO-BENZOTHIAZOLES AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-25 | — | — | WO | disclosed |
| US-20040229862-A1 | Imidazo-benzothiazoles | F. HOFFMAN-LA ROCHE AG (CH) | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583858-B2 | TDO2 inhibitors | TDO2, IDO2, TPH2 | RECQL 2350/4885USP2 1181/4885SMN1; SMN2 4338/4885 |
| US-20190016726-A1 | TDO2 Inhibitors | TDO2, IDO2, IDO1 | RECQL 3410/4885USP2 1087/4885SMN1; SMN2 4620/4885 |
| US-20220306635-A1 | TDO2 Inhibitors | TDO2, IDO2, IDO1 | RECQL 2017/4885USP2 797/4885SMN1; SMN2 4456/4885 |
| US-20040229862-A1 | Imidazo-benzothiazoles | ADORA1, ADORA3, ADORA2A | RECQL 729/4885USP2 4573/4885SMN1; SMN2 3421/4885 |
| US-10800780-B2 | TDO2 Inhibitors | TDO2, IDO2, IDO1 | RECQL 3410/4885USP2 1087/4885SMN1; SMN2 4620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.